NasdaqCM - Nasdaq Real Time Price USD

Ensysce Biosciences, Inc. (ENSC)

0.5410 -0.0300 (-5.25%)
At close: April 22 at 4:00 PM EDT
0.5750 +0.02 (+3.98%)
Pre-Market: 8:00 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
10,718.1870
10,718.1870
24,222.0950
19,870.4310
1,613.2870
Operating Income
-10,718.1870
-10,718.1870
-24,222.0950
-19,870.4310
-1,613.2870
Net Non Operating Interest Income Expense
-353.9450
-353.9450
-1,247.2650
-3,215.4650
-995.4960
Other Income Expense
445.8570
445.8570
1,261.6750
-6,060.0050
2,447.9080
Pretax Income
-10,626.2750
-10,626.2750
-24,207.6850
-29,145.9010
-160.8750
Net Income Common Stockholders
-10,626.0110
-10,626.0110
-25,085.4960
-29,886.8510
56.7700
Diluted NI Available to Com Stockholders
-10,626.0110
-10,626.0110
-25,085.4960
-29,886.8510
56.7700
Basic EPS
-4.69
--
-139.42
-355.68
0.56
Diluted EPS
-4.69
--
-139.42
-355.68
0.56
Basic Average Shares
2,264.0600
--
179.9250
84.0180
101.1480
Diluted Average Shares
2,264.0600
--
179.9250
84.0180
101.1480
Total Operating Income as Reported
-10,718.1870
-10,718.1870
-24,222.0950
-19,870.4310
-1,613.2870
Total Expenses
10,718.1870
10,718.1870
24,222.0950
19,870.4310
1,613.2870
Net Income from Continuing & Discontinued Operation
-10,613.0740
-10,613.0740
-24,172.2920
-29,083.7110
56.7700
Normalized Income
-11,043.5110
-11,043.5110
-28,957.6880
-23,305.9850
-2,391.1380
Interest Expense
353.9450
353.9450
109.5250
1,295.3070
995.4960
Net Interest Income
-353.9450
-353.9450
-1,247.2650
-3,215.4650
-995.4960
EBIT
-10,272.3300
-10,272.3300
-24,098.1600
-27,850.5940
834.6210
EBITDA
-10,272.3300
-10,272.3300
-24,098.1600
-27,850.4430
834.8220
Reconciled Depreciation
--
--
--
0.1510
0.2010
Net Income from Continuing Operation Net Minority Interest
-10,613.0740
-10,613.0740
-24,172.2920
-29,083.7110
56.7700
Total Unusual Items Excluding Goodwill
430.4370
430.4370
4,785.3960
-5,777.7260
2,447.9080
Total Unusual Items
430.4370
430.4370
4,785.3960
-5,777.7260
2,447.9080
Normalized EBITDA
-10,702.7670
-10,702.7670
-28,883.5560
-22,072.7170
-1,613.0860
12/31/2020 - 3/14/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

RNAZ TransCode Therapeutics, Inc.
0.4590
-5.36%
 
QNRX Quoin Pharmaceuticals, Ltd.
0.6600
-6.02%
 
KPRX Kiora Pharmaceuticals, Inc.
0.4850
-1.08%
 
SPRC SciSparc Ltd.
1.2200
-0.81%
 
REVB Revelation Biosciences, Inc.
2.0500
-8.48%
 
VRAX Virax Biolabs Group Limited
0.7050
+3.37%
 
NRBO NeuroBo Pharmaceuticals, Inc.
3.1200
-4.88%
 
ABVC ABVC BioPharma, Inc.
1.0400
+5.04%
 
ZVSA ZyVersa Therapeutics, Inc.
0.5748
-2.74%
 
TENX Tenax Therapeutics, Inc.
3.5600
-1.66%